alias::
ICD-11_Code::
tags:: #Disease, #[[Inflammatory Disease]], #Throat, #ENT

- ## Etiology
  background-color:: blue
	- ### Causative Agents
		- | **Type** | **Pathogens** |
		  | ---- | ---- | ---- |
		  | **Pyogenic** | *Staph. aureus*Â (MRSA if recurrent),Â *Klebsiella*, Anaerobes (*Fusobacterium*,Â *Bacteroides*) |
		  | **Granulomatous (TB)** | *Mycobacterium tuberculosis*Â (most common chronic cause) |
		  | **Fungal**Â (rare) | *Aspergillus*,Â *Histoplasma*Â orÂ *Blastomyces*Â (endemic fungi in immunocompromised). |
		  | **Other** | *Actinomyces*Â (sulfur granules) |
	- ### Risk Factors
		- **Incomplete treatment**Â of acute abscess
		- **Immunosuppression**Â (HIV, diabetes, steroids)
		- **TB exposure**Â (endemic regions, Pottâ€™s disease)
		- **Chronic ENT infections**Â (e.g., sinusitis, dental abscess)
- ## Epidemiology
  background-color:: blue
	- ### Incidence
		- Rare (<10% of all RPAs)
	- ### Prevalence
		- ### Demographics
			- Adults > Children
			- Elderly & immunocompromised at highest risk
	- ### Geographic Distribution
		- TB-associated : Endemic regions (Asia, Africa, Eastern Europe, South America)
- ## Pathophysiology
  background-color:: blue
	- ### Mechanism of Disease
		- **Chronic Fibrosis**: Incomplete resolution â†’ fibrotic encapsulation
		- **Granuloma Formation**: TB/fungal â†’ caseous necrosis
		- **Spread Routes**:
			- **Lymphatic**: TB from cervical nodes
			- **Direct**: Vertebral osteomyelitis (Pottâ€™s disease)
			- **Hematogenous**: Fungal (immunocompromised)
	- ### Affected Systems/Organs
		- **Retropharyngeal space**Â (between buccopharyngeal & alar fascia)
		- **Danger space**Â â†’ mediastinitis (if ruptures)
		- **Airway compression**Â â†’ stridor, respiratory failure
- ## Clinical Features #ent-prof-card #unanswered #card
  background-color:: blue
  deck:: #ENT
  id:: 25d8cef9-d646-4c62-a329-59dc6819cf92
	- ### Clinical Presentation
		- #### Symptoms
			- **Insidious onset**Â (weeks-months)
			- **Persistent throat discomfort**Â (less severe than acute)
			- **Odynophagia**, globus sensation, referred otalgia
			- **TB-specific**: Night sweats, weight loss, chronic cough
		- #### Signs
			- **Firm posterior pharyngeal bulge**Â (vs. fluctuant in acute)
			- **Low-grade fever**Â (unlike high fever in acute)
			- **Torticollis**Â (chronic muscle spasm)
			- Dysphonia (if recurrent laryngeal nerve is compressed)
		- Red Flags
			- ðŸš©Â **Stridor**Â â†’ airway compromise
			- ðŸš©Â **Mediastinitis**Â â†’ chest pain, dyspnea
- ## Diagnosis
  background-color:: blue
	- ### Diagnostic Criteria
		- Clinical suspicion + imaging confirmation
	- ### Investigation
	   #ent-prof-card #unanswered #card
	  deck:: #ENT
		- ### Establishing Diagnosis
			- ### **Imaging**
			  
			  | **Modality** | **Findings** |
			  | ---- | ---- | ---- |
			  | **CT Neck** | Thick-walled abscess Â± rim enhancement, vertebral destruction (TB) |
			  | **MRI** | Best for spinal/mediastinal extension |
			  | **CXR** | Mediastinal widening (if ruptured) |
			- ### **Biopsy & Labs**
				- **TB**: AFB stain, GeneXpert, culture (4-8 weeks)
				- **Actinomyces**: Sulfur granules (Gram+ filaments)
				- **Labs**: â†‘ESR/CRP, lymphocytosis(**More common in TB but nonspecific**)
		- ### Ruling Out Differential Diagnosis
			- |DD|Ruling Out|
			  |--|--|
			  | Acute RPA | Rapid onset, severe pain, high fever |
			  | Retropharyngeal tumor | No fever, progressive dysphagia |
			  | Pottâ€™s disease | Vertebral destruction on imaging |
		- ### General Assessment
			- CBC(lymphocytosis), ESR/CRP (elevated)
			- TB testing if endemic
- ## Management and Treatment #ent-prof-card #ent-prof-written #unanswered #card
  background-color:: blue
  id:: b74bd004-ee30-4dd4-abc5-fa18e986569f
  deck:: #ENT
	- ### Medical Treatment
		- Empirical antibiotics
			- **Empirical antibiotics**Â (4-6 weeks):
				- **Clindamycin + Ceftriaxone**Â (pyogenic)
				- Piperacilin-Tazobactam or CarbapenemsÂ (**for severe cases or immunocompromised**)
			- **TB**:Â **HRZE regimen**Â (6 months)
				- **H**Â â€“ Isoniazid
				- **R**Â â€“ Rifampin
				- **Z**Â â€“ Pyrazinamide
				- **E**Â â€“ Ethambutol
	- ### Surgical Options
		- **CT-guided drainage**Â orÂ **open cervicotomy**.
		- **Cervicotomy**Â (for large/complex abscesses)
		- **Spinal stabilization**Â (if vertebral collapse)
		- **Transoral drainage avoided in chronic RPA due to fibrosis/vascular risk**
	- ### Lifestyle and Dietary Recommendations
	- ### Follow-up
		- **Repeat imaging at 4-6 weeks**
		- **Monitor for complications**:
			- Mediastinitis (50% mortality if untreated)
			- Fibrotic strictures â†’ chronic dysphagia
- ## Prognosis
  background-color:: blue
	- ### Expected Course
		- #### With Treatment
			- **Surgical drainage + antibiotics resolve 80-90% of pyogenic cases**
			- TB-Specific : **Vertebral collapse may require long-term orthopedic follow-u**
		- #### Without Treatment
			- ##### Possible Complications
				- Fibrotic stenosis -> permanent dysphagia
				- Vertebral collapse (TB)
				- Airway Obstruction
			- ##### Long-Term Effects
	- ### Survival Rates
		- #### With Treatment
		- #### Without Treatment
	- ### Quality of Life Considerations
- ## Prevention
  background-color:: blue
	- ### Health Education
		- **Warning signs**: Dyspnea, severe dysphagia â†’ ER visit
	- ### Community Approach
		- TB prevention : BCG vaccine (endemic areas)
		- DOT
	- ### Screening Programs
	- ### Lifestyle Modifications
- ## Patient Education and Support
  background-color:: blue
	- ### Educational Resources
	- ### Support Groups
	- ### Counseling Options
- ## Recent Research and Developments
  background-color:: blue
	- ### Ongoing Clinical Trials
	- ### Recent Advances
- ## Key Literature
  background-color:: blue
- ## Guidelines and Protocols
  background-color:: blue
- #SN Short Note #ent-prof-written #unanswered #card
  deck:: #ENT
  id:: 6758118c-3559-4253-97b5-4b3a4592b1f5